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ABSTRACT  
Twenty five derivatives of the drugs terfenadine and ebastine have been designed, 
synthesized, and evaluated as inhibitors of recombinant human CYP2J2. Compound 14, that 
involves an imidazole substituent, is a good non competitive inhibitor of CYP2J2 (IC50 = 400 
nM). It is not selective towards CYP2J2 as it also efficiently inhibits the other main vascular 
CYPs, such as CYP2B6, 2C8, 2C9 and 3A4; however, it could be an interesting tool to inhibit 
all these vascular CYPs. Compounds 4, 5 and 13 that involve a propyl, allyl and benzo-1,3-
dioxole terminal groups, respectively, are selective CYP2J2 inhibitors. Compound 4 is a high-
affinity, competitive inhibitor and alternative substrate of CYP2J2 (Ki = 160 ± 50 nM). 
Compound 5 and 13 are efficient mechanism-based inhibitors of CYP2J2 (kinact/KI values 
~3000 L.mol-1.s-1). Inactivation of CYP2J2 by 13 is due to the formation of a stable iron-
carbene bond which occurs upon CYP2J2-catalyzed oxidation of 13 with a partition ratio of 
18 ± 3. These new selective inhibitors should be interesting tools to study the biological roles 
of CYP2J2. 
 
KEYWORDS 
Ebastine; terfenadine; drug metabolism; arachidonic acid epoxidation; vascular P450s; benzo-
1,3-dioxole; hydroxylation; monooxygenases; hemeproteins. 
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ABBREVIATIONS 
CYP or P450: cytochrome P450; DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; 
EDTA: ethylenediaminetetraacetic acid; EET: epoxyeicosatrienoic acid; ESI: electrospray 
ionization; GSH: glutathione, reduced form; HEPES: 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; HPLC: high performance liquid chromatography; MS: mass 
spectrometry; MS2: tandem mass spectrometry; THF: tetrahydrofuran; TLC: thin layer 
chromatography; Tris: 2-amino-2-(hydroxymethyl)-1,3-propanediol; UV: ultraviolet. 
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INTRODUCTION 
Cytochromes P450 (CYPs) constitute a superfamily of hemoproteins that play key roles in the 
metabolism of a large variety of xenobiotics and endogenous compounds [1]. In the human 
genome, 57 genes have been found to code for CYPs [2]. The main CYPs implicated in drug 
metabolism, such as CYP3A4, CYP2C9 or CYP2D6, and those responsible for the 
biosynthesis of steroid hormones have been extensively studied, and several x-ray structures 
of human CYPs have been recently published [3-10]. Much less is known about more recently 
discovered human CYPs such as CYP2J2 [2, 11, 12]. This cytochrome seems to be primarily 
expressed in heart [11]; it has also been found in kidney, liver, lung and the gastrointestinal 
tract [11-14]. CYP2J2 has been found to catalyze the epoxidation of arachidonic acid to four 
cis-epoxyeicosatrienoic acids (EETs), with regio- and stereo- selectivities that match those of 
the EETs isolated from heart tissue [11]. Some EETs-derived metabolites play important roles 
in the regulation of vascular tone [15, 16]. Moreover, it has been shown that CYP2J2-derived 
metabolites are involved in the recovery of heart function following ischemia in mice[17], 
that the risk of coronary artery disease is associated with polymorphisms in CYP2J2 gene in 
humans [18], and that CYP2J2-derived products are involved in cardiac electrophysiology 
[19, 20]. EETs and EETs-derived metabolites are also involved in a host of processes related 
to cancer cell behavior, angiogenesis and tumor pathogenesis [21, 22]. Very recent data 
suggest that CYP2J2 promotes the neoplastic phenotype of carcinoma cells and may represent 
a novel biomarker and potential target for therapy of human cancers [23]. Besides these 
possible roles in the metabolism of endogenous compounds, CYP2J2 could be implied in the 
metabolism of some drugs, especially at the intestinal level. Thus, CYP2J2 has been shown to 
contribute to the metabolism of three drugs, ebastine [24, 25], astemizole [26] and terfenadine 
[27]. 
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Little data are presently available on the active site topology and substrate specificity of 
CYP2J2 [2]. Quite recently, preliminary results have shown that it was possible to obtain 
high-affinity inhibitors for CYP2J2, by chemical modification of terfenadone [28], that is an 
isomer of ebastine and a derivative of the drug terfenadine (see Figure 1 and Table 1). This 
article describes the design, synthesis, and evaluation as CYP2J2 inhibitors of 25 derivatives 
of terfenadone and ebastine. It also reports the compared effects of these compounds towards 
the other main CYPs that are present in the vascular system, such as CYP2B6, 2C8, 2C9 and 
3A4. Finally, it describes a detailed study of the mechanism of inhibition of CYP2J2 by some 
of these compounds and reveals a high-affinity and selective, competitive inhibitor of 
CYP2J2, and two selective, mechanism-based inhibitors of CYP2J2. 
 
MATERIALS AND METHODS 
Commercial chemicals. 
All chemicals used in this study were of the highest purity available. Organic and HPLC 
solvents were purchased from SDS (Peypin, France); ebastine was provided by Almirall 
(Paris, France). NADP+, glucose 6-phosphate and glucose 6-phosphate dehydrogenase were 
purchased from Boehringer-Mannheim (Mannheim, Germany). Paclitaxel, amodiaquine, 
reduced glutathione (GSH), 7-benzyloxyresorufin, resorufin, diclofenac, testosterone, 
ticlopidine, sulfaphenazole and ketoconazole were obtained from Sigma chemicals (Lyon, 
France). 3',4'-Dihydroxypropiophenone and 3,4-(methylenedioxy)propiophenone were 
purchased from Alfa Aesar (Strasbourg, France). Montelukast was obtained from Sequoia 
Research (Oxford, UK). 
 
Physical measurements. 
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UV-visible spectra were recorded at room temperature using an Uvikon 941 
spectrophotometer. 1H NMR spectra were recorded at 27 °C on a Bruker ARX-250 
instrument; chemical shifts are reported downfield from (CH3)4Si and coupling constants are 
in Hz. The abbreviations s, d, t, q, m, bs, dd, dt, td and tt are used for singlet, doublet, triplet, 
quadruplet, massif, broad singlet, doublet of doublets, doublet of triplets, triplet of doublets 
and triplet of triplets, respectively. Mass spectra (MS) were performed using a LCQ 
Advantage-ion trap mass spectrometer (Thermo Finnigan, Les Ulis, France). MS ionization 
was carried out using an electrospray ionization (ESI) source in positive mode, with a 
capillary temperature of 275 °C, a capillary voltage of 21 V and a spray voltage of 5 kV. This 
ionization gave the molecular ion (M+H+) indicated for each compound. The mentioned 
fragments were obtained from tandem mass spectrometry (MS2) that was performed with 
activated broadband and a fragmentation power set to 40-50 %, depending on the substrate. 
Compound 11 contains one bromine atom, and all peaks corresponding to the molecular ion 
or fragments involving a Br atom exhibited the isotope cluster expected for the presence of 
one Br atom (with a M:M+2 ratio of 51:49). 
 
Synthesis of ebastine and terfenadone derivatives. 
All compounds were characterized by 1H NMR spectroscopy in CDCl3 and ESI-ion trap MS2 
in positive mode. 1H NMR spectroscopy analysis in the presence of an internal standard 
showed that all these compounds were more than 95 % pure. Most compounds were 
synthesized according to the scheme indicated on Fig. 2. This was the case of compounds 1, 
3, 4, 6-9, 11-13, 15 and 19-21. Compounds 5 and 14 were prepared from 11. Compound 17 
was synthesized by a very similar protocol using 4-(4-propylphenyl)butylmethane sulfonate 
as an intermediate. Compounds 2, 10, 16, and 25 were a gift from Dr. Didier Buisson (UMR 
8601, Paris); their syntheses will be described elsewhere (El Ouarradi et al., in preparation). 
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Finally, compounds 22, 23, and 24 were obtained from dehydration of 1, 15, and terfenadine, 
respectively. Compounds 1, 11, 20, 22 and 24 were reported in a patent [29]; however their 
1H NMR and mass spectrum characteristics were not described. The main 1H NMR and MS 
characteristics of compounds 1, 3, 4, 6, 9, 11-13, 15, 17, 5, 14, 7, 8, 19, 18, and 21-24 (in the 
order of appeareance in following paragraphs a) to h)) as well as those of some of their 
precursors are given in Supplementary Materials. 
 
a) Synthesis of the intermediates (see Fig. 2). 
4-(diphenylmethoxy)piperidine [30] and 1,1-difluoro-2-phenylethane [31] were prepared as 
described previously. 
Typical procedure for the synthesis of the intermediate alkylchlorides by Friedel-Crafts 
acylations. To a solution of aromatic starting compound C6H5-R (see Fig. 2) (15 mmol) and 
4-chlorobutanoyl chloride (15 mmol) in dry CH2Cl2, AlCl3 or SnCl4 (20 mmol) was 
progresssively added at room temperature under argon. After stirring at room temperature for 
2-18 h then at 40°C for 2-7 h, the mixture was poured into ice water and stirred overnight. 
The organic phase was separated and the aqueous phase was extracted with CH2Cl2. The 
combined extract was dried (MgSO4) and the solvent evaporated. Compounds were purified 
by column chromatography (SiO2) (cyclohexane/ethyl acetate 90/10). The obtained 
alkylchlorides were characterized by 1H NMR spectroscopy and used as such for the 
following reactions. 
Synthesis of 4-(4-propylphenyl)butylmethanesulfonate. 4-(4-Propylphenyl)butanoic acid was 
prepared as described previously [32, 33]. A solution of this carboxylic acid (1.03 g, 5 mmol) 
in THF (10 mL) was slowly added to a suspension of NaBH4 (227 mg, 6 mmol) in THF (10 
mL) at room temperature (10 min). The mixture was stirred until the end of gas emission. 
Iodine (635 mg, 2.5 mmol) in THF (10 mL) was then added slowly (10 min) at room 
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temperature. The medium was further stirred for 1h. Dilute HCl (7 mL, 1N) was added 
carefully and the mixture extracted with ether. The combined ether extracts were washed with 
1M NaOH and brine, and dried over MgSO4. Evaporation of the organic layer gave 4-(4-
propylphenyl)butan-1-ol which was purified by column chromatography on SiO2 (CH2Cl2 
then +10% ether), and was obtained as a pale yellow oil in a 61 % yield. 1H NMR (CDCl3): δ 
0.92 (3H, t, J = 7.3 Hz), 1.19 (1H, bs), 1.65 (6H, m), 2.56 (4H, m), 3.65 (2H, m), 7.07 (4H, s). 
Methanesulfonyl chloride (326 µL, 4.22 mmol) was then added to a stirred solution of this 
alcohol (405 mg, 2.11 mmol) in dry CH2Cl2 (6.5 mL) containing pyridine (1.48 mL) at 0°C. 
This solution was stirred under an argon atmosphere for 20 h at room temperature, diluted 
with CH2Cl2, washed with aqueous sulfuric acid (1%, 2 x 50 mL), saturated aqueous NaHCO3 
(50 mL), and brine, and reextracted with CH2Cl2. The combined organic phase was dried 
(MgSO4), and the solvent was removed under vacuum to afford a colourless oil (100% yield). 
1H NMR (CDCl3): δ 0.92 (3H, t, J = 7.6 Hz), 1.61 (2H, m), 1.65 (4H, m), 2.53 (2H, t, J = 7.6 
Hz), 2.61 (2H, m), 2.96 (3H, s), 4.21 (2H, t, J = 5.8 Hz), 7.07 (4H, s).  
 
b) General procedure for N-alkylation of α,α-diphenyl-4-piperidinomethanol 
(terfenadone derivatives) or 4-(diphenylmethoxy)piperidine (ebastine derivatives) [34], used 
for the synthesis of 1, 3, 4, 6, 7, 9, 11-13, 15, and 17. 
The piperidine derivative (1 eq.), anhydrous K2CO3 (2 eq.) and KI (0.2 eq.) were 
added to a solution of 4-chlorobutan-1-one-derived compounds (1 eq.) in dry DMF. The 
resulting mixture was refluxed under argon for 24 h. After cooling, the solvent was removed 
under vacuum to give a residue that was dissolved in CH2Cl2, washed with water, and dried 
over MgSO4. After evaporation of the solvent, products were purified by column 
chromatography on SiO2 (CH2Cl2 then 10% MeOH), and by dissolution in ether to filter the 
insoluble impurities.  
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c) Synthesis of 1-(4-allylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-
one, 5. 
Coupling of 11 (620 mg, 1.26 mmol) with allyltributyltin (0.5 mL) in DMF (13 mL) was 
performed in the presence of tetrakis(triphenylphosphine)palladium(0) (90 mg) under argon, 
30 min at room temperature then 6 h at 110°C. Purification by column chromatography (SiO2 
CH2Cl2 - MeOH 95:5) led to compound 5 as a white powder in 45% yield.  
 
d) Preparation of 1-(4-N-imidazolylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-
yl)butan-1-one, 14.  
Coupling of 11 (0.13 mmol) with imidazole (0.16 mmol) was performed in the presence of 
CuI (0.013 mmol), proline (0.13 mmol) and K2CO3 (0.26 mmol) [35]. The reaction was 
performed under argon at 95°C during 40 h. After ethyl acetate extraction and drying on 
anhydrous MgSO4, 14 was purified on SiO2 (CH2Cl2/MeOH 90:10) and led to a brown oil (54 
% yield) 
 
e) Preparation of 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-(2-
hydroxyethyl)phenyl)butan-1-one, 7, 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-(3-
hydroxypropyl)phenyl)butan-1-one, 8, and 4-(4-(diphenylmethoxy)piperidin-1-yl)-1-(4-(2-
hydroxyethyl)phenyl)butan-1-one, 19, from their acetate precursors. 
The acetate precursor (1 mmol) was heated under reflux in 5 mL EtOH with 70 mg NaOH 
(1.75 mmol) for 2.5 h. After evaporation of EtOH, the residue was diluted with water and 
extracted with CH2Cl2. The organic phase was dried over MgSO4. After evaporation of the 
solvent, compounds 7, 8 and 19 were purified by column chromatography (SiO2, CH2Cl2 - 
EtOH 90:10) and by dissolution in ether to filter insoluble impurities. 
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f) Synthesis of 4-(4-(diphenylmethoxy)piperidin-1-yl)-1-(4-(2-tertiobutyl)phenyl)butan-
1-ol, 18, from reduction of ebastine. 
A suspension of NaBH4 (64,4 mg, 1.7 mmol) in MeOH (4 mL) was slowly added to a solution 
of ebastine (200 mg, 0.4 mmol) in distilled THF (8 mL) at 0°C. After 7h of stirring, HCl (1 
mL, 1 M) was added to hydrolyze residual NaBH4 and the mixture was extracted with ethyl 
acetate. The combined extract was washed with brine and dried over Na2SO4. After filtration, 
18 was purified by column chromatography on SiO2 (CH2Cl2 then  5 % MeOH) and was 
obtained as white powder in 81 % yield. 
 
g) Synthesis of (4-[4-(diphenylmethoxy)piperidin-1-yl]-1-(4-vinylphenyl)butan-1-one, 
20, and 4-[4-(diphenylmethoxy)piperidin-1-yl]-1-[4-(2-thiomethoxy)ethylphenyl]butan-1-one, 
21, from 19.  
Compound 19 (100mg, 0.22mmol) in the presence of ethylamine (30µL, 0.21 mmol) was 
cooled to 0°C in CH2Cl2 (2mL). Methanesulfonyl chloride (20 µL, 0.26 mmol) was added and 
the reaction mixture was kept at 0°C for 2h. After evaporation, 2-(4-{4-[4-
(diphenylmethoxy)piperidin-1-yl]-1-oxobutyl}phenyl)ethyl methanesulfonate was purified by 
column chromatography (SiO2, CH2Cl2 then 7 % EtOH). Then, dissolution in ether to filter 
insoluble impurities gave the desired product (110mg, 0.21 mmol, 95 % yield). 1H NMR 
(CDCl3): δ 1.66 (2H, m), 1.91 (4H, m), 2.12 (4H, m), 2.37 (2H, t, J = 7.1 Hz), 2.86 (3H, s), 
2.95 (2H, t, J = 7.1 Hz), 3.09 (2H, t, J = 6.7 Hz), 3.40 (1H, m), 4.42 (2H, t, J = 6.7 Hz), 5.48 
(1H, s), 7.17-7.30 (12H, m), 7.91 (2H, d, J = 8.3 Hz). MS2 (ESI+): m/z 536 (M + H+), 269, 
227, 167. Reaction of this methanesulfonate derivative (1 eq.) with 2eq. of EtONa  in 2 mL 
MeOH at 50°C for 20h gave 20, whereas a very similar reaction with 1 eq. of CH3SNa in 1.5 
mL dry DMF led to 21. The reaction mixtures were extracted with CH2Cl2 and the products 
were purified by chromatography on SiO2 (CH2Cl2 then 7 % MeOH).  
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h) Synthesis of 4-[4-(diphenylmethylene)piperidin-1-yl]-1-[4-tertiobutylphenyl]butan-
1-one 22, 1-[4-(2-aminoethyl)phenyl]-4-[4-(diphenymethylene)piperidin-1-yl]butan-1-one 23, 
and  4-(diphenylmethylene)-1-[4-(4-tertiobutylphenyl)but-3-enyl]piperidine hydrochloride 24, 
from dehydration of 1, 15 and terfenadine, respectively. 
Derivative 1 (100 mg, 0.2 mmol) in 10 mL HCl (3 M, 30 mmol) was heated to reflux for 6h. 
After neutralization, the reaction mixture was extracted with CH2Cl2 and compound 22 was 
purified by TLC on SiO2 (ethyl acetate, then 20 % EtOH).  
 
Origins of recombinant cytochromes P450. 
 CYP2J2 was co-expressed with human P450 reductase in baculovirus-infected Spodoptera 
frugiperda insect cells (Sf9) and microsomes of these cells were prepared as described 
previously [11]. CYP2B6, 2C8, 2C9 and 3A4 were expressed in a previously described yeast 
strain W(R)fur1 [36] system, in which yeast cytochrome P450 reductase was overexpressed. 
Transformation by a pYeDP60 vector containing one of the human liver CYP2B6, 2C8, 2C9 
and 3A4 cDNAs  was then performed according to a general method of construction of yeast 
strain W(R)fur 1 expressing various human liver P450s [37-39]. Yeast culture and 
microsomes preparation were performed by using previously described techniques [40]. 
Microsomes were homogenized in 50 mM Tris buffer (pH 7.4) containing 1 mM EDTA and 
20% glycerol (v/v), aliquoted, frozen under liquid N2, and stored at -80 °C until use. P450 
contents of yeast microsomes or insect cell microsomes were 90, 30, 30, 300 and 100 pmol 
P450/mg protein for CYP2B6, 2C8, 2C9, 3A4, and 2J2 respectively. Those contents were 
determined spectrally using the method of Omura and Sato [41]. Some comparative 
experiments were done using microsomes from baculovirus-infected insect cells expressing 
CYP 2B6, 2C8, 2C9, and 3A4 (Supersomes from BD Discovery Labware, Woburn, MA, 
USA). 
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Enzyme activity assays.  
 a) Hydroxylation of ebastine. The assay for hydroxylation of ebastine by CYP2J2 [24] 
was performed at 37 °C in the presence of a NADPH-generating system (1 mM NADP+, 10 
mM glucose 6-phosphate, and 2 units/mL glucose 6-phosphate dehydrogenase) using a 
previously described method [28]. The concentrations of ebastine and CYP2J2 were 0.5 µM 
and 1 nM, respectively. The reaction was done at 37 °C for 2 to 5 min. 
b) O-Debenzylation of 7-benzyloxyresorufin. The protocol used for measuring the 
oxidation of 7-benzyloxyresorufin by CYP2B6 was based on a modification of the 
spectrofluorometric method described by Burke and Mayer [42]. A mixture containing 0.5 
µM 7-benzyloxyresorufin and yeast microsomes expressing CYP2B6 (10 nM) in 100 mM 
HEPES buffer pH 7.8 containing 5 mM MgCl2 for a total volume of 985 µL was preincubated 
at 37 °C for 3 min. Reaction was started with the addition of NADPH (100 µM) and 
formation of resorufin was monitored by fluorimetry, with an excitation wavelength of 535 
nm and an emission wavelength at 580 nm. After 2 to 3 min, during this fluorimetric 
monitoring, inhibitor was added and the change of slope of the activity vs. time curve was 
observed. Then, quantitation of metabolite was done by addition of authentic resorufin (20 
nM final concentration). 
  c) 6a-Hydroxylation of paclitaxel. Hydroxylation of paclitaxel by CYP2C8 [43] was 
assayed as described previously [44] (10 µM substrate, 10 nM CYP2C8, 5 min at 28 °C).  
d) N-Deethylation of amodiaquine. N-deethylation of amodiaquine by microsomes of 
yeast cells expressing CYP2C8 was performed according to a previously reported procedure 
[45] (1 µM substrate, 10 nM CYP2C8, 10 min at 28 °C). 
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e) 4’-Hydroxylation of diclofenac. Diclofenac hydroxylation by CYP2C9 was carried 
out using a previously reported protocol [46] (15 µM substrate, 20 nM CYP2C9, 10 min at 28 
°C). 
f) 6β-Hydroxylation of testosterone. The assay for testosterone 6β-hydroxylation  was 
performed as described previously  [47] (20 µM substrate, 10 nM CYP3A4, 20 nM 
cytochrome b5, 10 min at 28 °C). 
 
Study of CYP2J2 inactivation by derivatives 5 and 13. 
a) General incubation procedure. All incubations were performed at 37 °C in 
triplicate, using glass tubes in a shaking bath. The incubation mixture contained insect cell 
microsomes expressing CYP2J2, an inhibitor, and a NADPH-generating system in 0.1 M 
phosphate buffer pH 7.4 containing 1 mM EDTA.  
b) Time course analysis of the oxidation of compound 13 by CYP2J2-expressed insect 
cell microsomes. Compound 13 was incubated at 37 °C in the presence of insect cell 
microsomes expressing CYP2J2 (10 nM) and reaction was started by the addition (t0 = 0 min) 
of the NADPH-generating system, which had been pre-incubated at 37 °C for 3 min (total 
final volume of 2 mL). At t0 and regularly thereafter, aliquots (200µL) were taken and were 
mixed with 100 µL of a cold CH3CN/CH3COOH (10:1) mixture to quickly stop the enzymatic 
reaction. Proteins were precipitated by centrifugation at 10 000 rpm for 10 min, and the 
supernatant was stored at –40°C for HPLC/MS/UV analysis. The apparatus for HPLC/MS-
UV analysis was composed of a Surveyor HPLC system and LCQ Advantage-ion trap mass 
spectrometer (Thermo Finnigan, Les Ulis, France). Elution was carried out on a Betabasic-18 
column (100 × 2.1 mm, 3.5 µ) (Thermo Finnigan, Les Ulis, France). The mobile phase 
consisted of water/acetonitrile/formic acid (80/20/1) (solvent A) and acetonitrile/formic acid 
(99/1) (solvent B), at a flow rate of 200 µL/min. Elution was performed with a linear gradient 
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from 0% to 45 % B in 5 min, followed by an increase of B to 55% in 17 min, and by 4 min at 
100 % B. Quantification of the metabolite formed was carried by monitoring of the effluent at 
310 and 275 nm.  
 
c) Incubation for inactivation kinetics. The experimental protocols for determining the 
kinetic parameters of CYP2J2 inactivation were based on the previously described procedures 
for other mechanism-based inhibitors [48-50]. Insect cells microsomes (30 nM P450) were 
incubated under the conditions described above, in the presence of inhibitor concentrations 
ranging from 1 to 20 µM. At t0 and regularly thereafter, aliquots (25 µL) were removed from 
the incubation medium and immediately processed to determine residual ebastine hydroxylase 
activity.  
d) Determination of the residual monooxygenase activity. Routine experimental 
procedures to determine the enzymatic activity remaining after exposure to a suicide substrate 
[50] need the use of an alternative substrate to assay the remaining activity in a second 
incubation period. To dramatically decrease the influence of the already present inactivator 
substrate on the accurate determination of enzymatic activity, samples were diluted 20-fold in 
the standard medium assay. Briefly, 25 µL aliquots taken from CYP2J2 inactivation 
experiments were rapidly diluted in a total volume of 500 µL containing 20 µM ebastine and 
a NADPH-generating system. At t0 = 0 min, 150 µL aliquots were removed and quenched by 
adding 75 µL of CH3CN/CH3COOH (10:1) cold mixture and vortexing. The remaining 
medium was incubated at 37°C and two other 150µL aliquots were removed at t = 2 and 4 
min to be treated as the first one. In all experiments, the initial rate for ebastine hydroxylation 
activity was taken as a measure of the maximal activity (100 % activity). 
e) Effect of a competitive inhibitor and glutathione on CYP2J2 inactivation by 
compound 13. Incubations for inactivation measurement were carried out as described above 
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in order to determine the time course of enzyme inactivation in the presence of compound 4 
or GSH. Compound 4 (50 µM) or GSH (5 mM) were added at t0 of the inactivation incubation 
assay containing 5 µM compound 13. At the indicated times, the residual activity was 
determined as described above. 100% activity was defined for remaining activity measured at 
t0 for each incubation conditions. Control assays under non-catalysis conditions (in the 
absence of the NADPH-generating system) were carried out in parallel with the experimental 
incubations. 
f) Inactivation kinetics analysis. Kinetic parameters of the inactivation process were 
calculated according to previously described models [48, 50]. This process can be represented 
in the simplest way by the following equations:  
 
where ES is the initial enzyme-substrate complex converted to an activated species, ES*, that 
can either react with the enzyme which leads to inactivated enzyme (EI), or break down to 
yield free enzyme and product (P). k
-1/k1 represents the dissociation constant KS, and k3/k4 is 
the partition ratio between the number of productive turnovers and the number of turnovers 
leading to enzyme inactivation. The pseudo-first order rate constant for the inactivation 
process (kinact) is k2k4/(k2 + k3 + k4). The KI constant, a term used for mechanism-based enzyme 
inactivators, is [(k
-1 + k2)/k1][(k2 + k4)/(k2 + k3 + k4)]. Calculation of those constants were 
performed using the analytical treatment described by Kitz and Wilson [51]. 
  g) UV-visible spectra observed during interaction of compound 13 with CYP2J2. A 
suspension of microsomes from insect cells expressing CYP2J2 (100 nM P450) in 0.1 M  
phosphate buffer, pH 7.4, containing 0.1 mM EDTA was equally divided between two 200 µL 
black quartz cuvettes (1 cm path length). 3 µL of a DMSO solution of compound 13 were 
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added to the sample cuvette, the same volume of solvent being added to the reference cuvette, 
and a baseline was recorded between 350 and 500 nm. 2 µL of NADPH (final concentration 
of 100 µM) was then added (t0 = 0 min) to the sample cuvette and difference spectra were 
recorded at t0 and every min thereafter for 20 min between 350 and 500 nm. 
 
RESULTS AND DISCUSSION 
Synthesis of three series of derivatives of terfenadone, dehydroterfenadone and ebastine. 
The choice of terfenadone, 1, and ebastine as starting points for the design of high-affinity 
inhibitors of CYP2J2 was based on: (i) the high regioselectivity of the CYP2J2-catalyzed 
hydroxylations of 1 and ebastine, in favor of the least reactive part of these substrates (Fig.1), 
which implies their strict positioning in the CYP2J2 active site to keep their t-butyl group in 
close proximity of the heme iron for transfer of an oxygen atom from O2, and (ii) the high 
affinity of 1 and ebastine for CYP2J2, as indicated by the IC50 value of 1 for CYP2J2 
inhibition (0.7 µM) [28] and the Km of CYP2J2-catalyzed hydroxylation of ebastine (1 µM) 
[24].  
Sixteen derivatives of terfenadone were synthesized and compared to terfenadone and the 
drug terfenadine, as CYP2J2 inhibitors (Table 1). Most of them derive from terfenadone by 
replacement of its t-butyl group with various R groups of different size and polarity. This 
includes R groups bearing chemical functions well known to lead to suicide inactivation of 
cytochrome P450 after in situ oxidation [52-56]. This is the case of the terminal double bond 
of compound 5, of the CHF2 function of compound 12, and of the benzo-1,3-dioxole function 
of compound 13 (Table 1). The structure of compounds 5, 12 and 13 was chosen so that the 
CYP2J2-catalyzed hydroxylation occurs at the site leading to inactivating metabolites, 
assuming that hydroxylation of these compounds should occur on the homobenzylic position, 
as the hydroxylation of terfenadone [28], terfenadine [27] and ebastine [24]. The general 
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synthetic route used for the preparation of the terfenadone and ebastine derivatives has been 
described previously [28]; it is recalled in Figure 2. Compounds 16 and 17, in which the keto 
group of 1 and 4 was replaced with a CH2 group, were also synthesized to evaluate the 
importance of this keto group in CYP2J2 inhibition. Compounds 5 and 14 were obtained from 
reaction of 11 with allytributyltin and imidazole, respectively. In the ebastine series, 
compounds 20 and 21 were prepared from reactions of the methanesulfonate of 19 with 
sodium ethanolate and sodium thiomethoxide, respectively (see Materials and Methods). 
Finally, compounds 22, 23 and 24, that are derived from dehydro-terfenadone, were obtained 
by treatment of compounds 1, 15 and terfenadine by HCl in boiling water. All compounds 
were characterized by 1H NMR spectroscopy and mass spectrometry. 1H NMR spectroscopy 
in the presence of an internal standard showed that all these compounds were more than 95 % 
pure. 
 
Comparison of the inhibitory effects of the terfenadone and ebastine derivatives towards 
CYP2J2. 
The fourth columns of Tables 1, 2 and 3 compare the IC50 values found for the inhibition of 
ebastine hydroxylation catalyzed by recombinant CYP2J2 expressed in baculovirus-infected 
Sf9 insect cells. These IC50 values vary from 0.4 to 23 µM. 
The presence of a terminal hydrophobic group (Ph2CHO-, Ph2C(OH)- or Ph2C=) in ω position 
relative to the hydroxylation site is important for the affinity of the inhibitors. This is 
indicated by the IC50 value of 25 that is 19-fold higher than that of terfenadone 1 (13 and 0.7 
µM, respectively). The hydrophobicity of this terminal group appears to be the most 
important factor for the affinity, as the removal of the tertiary alcohol function of 1 or of the 
ether function of ebastine resulting in 22 does not lead to any significant loss of affinity (IC50 
of 0.7 and 1 µM for 1 and ebastine to be compared to an IC50 of 0.9 µM for 22). 
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The presence of the keto function para to the R group is also important for the affinity of the 
compounds. This is shown by the marked increase of the IC50 value observed after reduction 
of the CO function of 1 into CHOH or CH2 functions (0.7, 8 and 3.6 µM for 1, terfenadine 
and 16 respectively). Similar increases of IC50 by a factor of about 10 were also found when 
passing from 4 to 17 and from 22 to 24 (Tables 1 and 3). 
The nature of the R substituent has a great influence on the affinity of the inhibitors towards 
CYP2J2. The best results were obtained with hydrophobic C3 alkyl chains, as the lowest IC50 
values were observed for compounds 4 and 5 (0.4 µM) for which R is a propyl or an allyl 
group. Any increase or decrease of the chain length, as in 6 or 3 respectively, led to an 
increase of the IC50 value. Moreover, the introduction of polar groups into R always led to a 
marked increase of the IC50 (compare for instance 7, 8, 9, and 15 with 4 or 6, and 10 with 3). 
In that regard, the low IC50 value observed for compound 14, for which R is a quite polar 
imidazole group, is a particular case. Its good affinity for CYP2J2 is due to the presence of the 
imidazole heterocycle, which is a well-known ligand of P450 iron [52] and should strongly 
bind to the iron of CYP2J2. Accordingly, addition of 14 to a suspension of microsomes from 
insect cells expressing CYP2J2 led, in difference visible spectroscopy, to a spectrum 
characterized by a peak at 432 nm and a trough at 415 nm (type II difference spectrum [57]) 
(data not shown). These data confirmed that 14 binds to CYP2J2 iron through the accessible 
nitrogen atom of its imidazole moiety. 
 
Selectivity of the inhibitors towards CYP2J2 by comparison with other vascular P450s. 
Tables 1-3 also compare the inhibitory effects of the terfenadone and ebastine derivatives 
towards the other main CYPs that have been reported to be present in the vascular vessels, 
namely CYP2B6, 2C8, 2C9 and 3A4 [58-61]. The reference activities that were followed to 
measure these inhibitory effects were 7-benzyloxyresorufin O-debenzylase [42], paclitaxel 
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6α-hydroxylase [43], diclofenac 4’-hydroxylase [62] and testosterone 6β-hydroxylase [47] 
respectively. The substrate concentrations used in these experiments were equal to the Km of 
the activity followed for each CYP (see Materials and Methods). Microsomes of the 
W(R)fur1 yeast strain expressing each CYP and overexpressing yeast cytochrome P450 
reductase [36] were used. We have checked that the IC50 values measured with these systems 
were very similar to those measured by using microsomes of insect cells expressing CYP 
2B6, 2C8, 2C9, and 3A4 in the case of compounds 1, 3-6, 11, 13, 14 and 17 (less than 15 % 
variation of the IC50 values). 
Among all the studied compounds, the imidazole derivative 14 exhibited a particular 
behavior, as it acted as a good, but non selective inhibitor of all the studied CYPs, with IC50 
values from 0.4 to 5.2 µM. However, it is noteworthy that it exhibited the best affinity for 
CYP2J2 (IC50 = 0.4 µM). Even though 14 is not a selective inhibitor for CYP2J2, it could be 
useful to inhibit all the vascular CYPs and, consequently, all the activities of arachidonic acid 
epoxidation at the vascular level. 
As far as all the other compounds mentioned in Tables 1-3 are concerned, the main 
conclusions drawn from those tables are the following ones: 
i) none of the studied compounds led to a significant inhibition of CYP2C8 (IC50 > 100 µM). 
In order to confirm these results, we have also studied the effects of the terfenadone and 
ebastine derivatives towards another usual CYP2C8 activity, the N-deethylation of 
amodiaquine [45]. Both CYP2C8-catalyzed activities were not significantly inhibited by 
compounds 1-25, their IC50 values always being higher than 100 µM. 
ii) CYP2C9 was inhibited with IC50 values between 10 and 69 µM, that were, in general, 
about 10 fold higher than those found for CYP2J2. 
iii) the previous conclusion concerning CYP2C9 is globally valid for CYP2B6, with IC50 
values varying from 7 to 90 µM, if one excludes compound 23 that appeared to be a very 
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good inhibitor of CYP2B6. This inhibitory effect of 23 towards CYP2B6, and to a lesser 
extent towards CYP2J2, could be due to a strong binding of its terminal NH2 function to P450 
iron. 
iv) the studied compounds inhibited CYP3A4 with IC50 values from 0.9 to 68 µM, that were 
generally intermediate between those found for CYP2J2 and for CYP2C9 (or 2B6). 
The best inhibitors of CYP2J2, 4 and 5, are reasonably selective towards this cytochrome as 
their IC50 values towards the other studied CYPs are at least 20-fold (for 4) and 14-fold (for 5) 
higher than those found for CYP2J2.  
This preliminary study of the IC50 values of the terfenadone and ebastine derivatives allowed 
us to select the following compounds for further, more detailed studies. Compound 4 was 
chosen because of its IC50 value of 0.4 µM that was the lowest one and of its good selectivity 
towards CYP2J2. The choice of compound 14 was made because of its low IC50 and because 
it could be considered as an inhibitor for all the main vascular CYPs. Finally, compounds 5 
and 13 were selected because preliminary experiments showed us that their inhibitory effects 
increased as a function of the incubation time, suggesting that they could be mechanism-based 
inhibitors of CYP2J2. 
 
Study of the mode of inhibition of CYP2J2 by 4. 
Kinetic studies of the inhibition of CYP2J2-catalyzed hydroxylation of ebastine by 4 were 
performed at various ebastine (0.2 to 5 µM) and 4 (0 to 2 µM) concentrations. The 
Lineweaver-Burk plots of the reciprocal of the reaction rate vs the reciprocal of ebastine 
concentration, at different concentrations of 4, indicated that 4 acts as a competitive inhibitor 
of CYP2J2 (intercept of the straight lines on the y axis [63], data not shown). The Dixon plot 
of 1/v vs the concentration of 4 led to a Ki value for the inhibition of CYP2J2 by 4 of 0.16 ± 
0.05 µM (Figure 3). This value was in excellent agreement with the Ki value (0.2 µM) that 
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may be calculated from the IC50 value of Table 1, assuming that Ki=IC50/2 for a competitive 
inhibitor [64]. 
Actually, 4 is a substrate of CYP2J2; it is hydroxylated at the level of its propyl group, as 
expected from its great analogy with terfenadone (P. Lafite et al., publication in preparation). 
Thus, compound 4 is a competitive inhibitor and an alternative substrate of CYP2J2. We have 
checked that the concentration of 4 did not vary in a significant manner (less than 10 % 
consumption) under the conditions used in kinetic experiments of study of its inhibitory 
effects towards CYP2J2-catalyzed hydroxylation of ebastine (very low CYP2J2 concentration 
of 1 nM and short incubation times, 2-4 min). 
 
Characterization of the inhibition of CYP2J2 by 14. 
In order to analyze the type of inhibition of CYP2J2 by 14, the Lineweaver-Burk plots of the 
reciprocal of the reaction rate vs the reciprocal of ebastine concentration were drawn at 
different 14 concentrations. Figure 4 shows that 14 acts as a mixed-type inhibitor of CYP2J2, 
with a competitive and a non-competitive component [65]. The Dixon plot drawn for the 
inhibition of CYP2J2-catalyzed hydroxylation of ebastine by 14 led to an evaluation of the 
competitive and the non-competitive inhibition constants KiC and KiNC, respectively (data not 
shown). The values deduced from the Dixon plot, KiC = 0.2 ± 0.1 µM and KiNC = 2.4 ± 0.4 
µM, suggest that 14 is a mixed-type inhibitor, with a strong competitive component, as KiC is 
10-fold higher than KiNC. 
 
Mechanism of inhibition of CYP2J2 by compounds 5 and 13. 
To further analyze the time-dependent variation of the inhibitory effects of 5 and 13, insect 
microsomes containing recombinant CYP2J2 were preincubated with 5 or 13 in the presence 
or absence of NADPH (i.e. under catalysis or non catalysis conditions), and the remaining 
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enzymatic activity was measured using ebastine as substrate, as a function of the 
preincubation time. 
Incubation of microsomes with 5 in the presence of NADPH led to a progressive loss of 
CYP2J2 activity as a function of time (Fig. 5A). With 20 µM 5, 50 % of the activity was lost 
after 7 min and only 20 % remained after 20 min. Loss of CYP2J2 activity was faster after 
incubation with identical concentrations of 13, as 50 % of the activity was lost after 1.5 min 
and only 20 % remained after 4 min in the presence of 20 µM 13 (Fig. 5B). Incubations under 
identical conditions but in the absence of NADPH did not lead to any significant loss of 
CYP2J2 activity. In the absence of either 5 or 13, less than 10 % of the activity was lost after 
10 min (data not shown). These results confirmed the existence of a catalysis-dependent 
inactivation of CYP2J2 upon oxidation of 5 and 13. 
Kinetics of CYP2J2 inactivation by 5 and 13. 
Figure 5A shows that the loss of CYP2J2 activity as a function of time after incubation in the 
presence of NADPH and various 5 concentrations followed the classical kinetics previously 
described for other CYP suicide-substrates [54, 55]. The time required for half-maximal 
inactivation, t1/2, and the apparent first-order constant, kinact, were calculated from the 
logarithmic transformation of the remaining activity as a function of time, as depicted in 
Figure 5A. Plots of t1/2 versus reciprocal 5 concentration (Figure 5A, inset) led to the kinetic 
constants of the inactivation process (see Materials and Methods). From extrapolation to 
infinite 5 concentration, the time required to inactivate half of the enzyme, at the maximal 
rate, t1/2max, and the maximal kinact were 8.7 ± 2.2 min and 0.08 ± 0.02 min-1, respectively 
(Table 4). The inhibition constant, KI, was found to be 0.45 ± 0.05 µM, and the second-order 
rate constant kinact/KI, a proper index of the in vitro effectiveness of a compound as inactivator 
[66], was found to be 2960 ± 1000 L.mol-1.s-1. 
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Identical experiments were performed in the case of compound 13 (Figure 5B) and led to the 
kinetic constants reported in Table 4. The efficiencies of 5 and 13 as inactivators of CYP2J2 
are similar, if one compares their kinact/KI values (2960 and 2700 L.mol-1.s-1, respectively). In 
fact, the inactivation rate of CYP2J2 by 13 is 6-times higher than that found in the case of 5 
(0.47 ± 0.05 instead of 0.08 ± 0.02 min-1). At the opposite, the affinity of 5 for CYP2J2 seems 
to be higher than that of 13, as suggested by the KI (0.45 ± 0.05 and 2.9 ± 0.2 µM 
respectively, Table 4) and IC50 values (0.4 ± 0.1 and 6.7 ± 2 µM, respectively, Table 1) found 
for these compounds. Table 4 also compares kinetic constants reported for other CYP 
mechanism-based inactivators [56]. It indicates that 5 and 13 are reasonably efficient 
mechanism-based inactivators of CYP2J2, as judged from their kinact/KI values.   
Study of the molecular mechanism responsible for CYP2J2 inactivation by 13. 
Compound 13 has been designed to be a mechanism-based inhibitor of CYP2J2, as we 
expected that its hydroxylation by this enzyme would mainly occur at the level of its 
benzodioxole CH2 group. Such P450-dependent oxidations of benzo-1,3-dioxole derivatives 
are well known to lead to the formation of the corresponding catechol metabolites and to P450 
inactivation due to the formation of very stable P450 iron-benzodioxole-derived carbene 
complexes [52] (Figure 6). The generally admitted mechanism of these reactions involves the 
free-radical abstraction of an hydrogen atom of the benzodioxole CH2 group by the high-
valent P450 iron-oxo active species. The resulting radical may either undergo an oxidative 
transfer of the OH ligand of the P450 Fe(IV)-OH intermediate, with formation of an unstable 
orthoformiate that is eventually hydrolyzed to the corresponding catechol, or bind to P450 
iron leading to a very stable P450 iron-carbene complex after elimination of H2O [67, 68]. 
Addition of NADPH to microsomes of insect cells expressing CYP2J2 containing 100 µM 13 
led to the progressive appearance of a difference visible spectrum characterized by two peaks 
at 428 and 457 nm (Figure 7). This difference spectrum is characteristic of the formation of a 
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P450 iron-benzodioxole-derived carbene complex [52]. Under the used conditions (0.1 µM 
CYP2J2, 100 µM 13), the difference spectrum reached its maximal intensity 10 min after the 
addition of 100µM NADPH. If one considers the ε455-490 nm values reported in the literature 
for the difference spectra of these P450 iron-carbene complexes, which vary from 50 000 to 
75 000 M.cm-1 [69, 70], one may estimate that 66 to 99 % of CYP2J2 is engaged in an iron-
carbene complex derived from 13. 
Reaction mixtures from incubation of 13 with microsomes from insect cells expressing 
CYP2J2 in the presence of NADPH were studied by HPLC coupled to mass spectrometry. 
The major metabolite detected by this method exhibited a mass spectrum characterized by a 
molecular ion at m/z = 446 (M-12 if M is the molecular ion of 13). This ion well 
corresponded to the one expected for the catechol derived from 13. Moreover, the main 
fragments appearing in the mass spectrum of the metabolite were also in complete agreement 
with what could be expected for the catechol derived from 13. Thus, most fragments exhibited 
m/z values equal to those of 13 minus 12, except the fragments that do not contain the 
benzodioxole moiety which exhibited m/z values identical to chose of the corresponding 
fragments of 13 (Figure 8). Finally, comparison of the UV spectra of 13 and of its main 
metabolite showed very similar characteristics with two peaks at 280 and 305-310 nm, and a 
small blueshift of the 305-310 nm peak for the metabolite of 13. A comparison of the UV 
spectra of analog compounds, 3’,4’-(methylenedioxy)-propiophenone and the corresponding 
catechol, led to very similar characteristics (data not shown). 
The aforementioned data confirmed that CYP2J2-catalyzed oxidation of 13 mainly occurred 
at the benzodioxole CH2 group with formation of the corresponding catechol metabolite and 
of a CYP2J2 iron-carbene complex that leads to the inactivation of this cytochrome. 
Further studies of the characteristics of CYP2J2 inactivation by 13. 
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Figure 9A shows that the loss of CYP2J2 activity upon incubation with 2 µM 13 for 
increasing times paralleled catechol metabolite formation, as expected for mechanism-based 
inhibition [48-50]. Figure 9B illustrates the correlation between the CYP2J2 activity 
remaining after oxidation of 13 and the amount of catechol metabolite formed for various 
concentrations of 13 and incubation times. The linear relationship observed allowed us to 
estimate the partition ratio of the inactivation process, r, which represents the number of 
productive turnovers (leading to the catechol metabolite) divided by the number of 
inactivating events [48-50]. Actually, extrapolation to 0 % remaining activity in Fig. 9B led to 
a r value of 18 ± 3.  
The presence of 4, a good competitive inhibitor and alternative substrate of CYP2J2, in 
incubations of CYP2J2 with 13 and NADPH led to a clear decrease of the rate of inactivation 
of CYP2J2 (see figure in Supplementary Materials). 
An important property of efficient mechanism-based inhibitors is to generate reactive species 
that will rapidly react within the active site rather than diffuse out into solution. The presence 
of 5 mM reduced glutathione in incubations of CYP2J2 with 13 and NADPH did not have any 
significant effects on the rate of CYP2J2 inactivation (see figure in Supplementary Materials). 
This result indicates that the reactive intermediate of 13 that is responsible for CYP2J2 
inactivation is not an electrophilic metabolite released in the medium. It is in agreement with 
the mechanism shown in Figure 6, in which the free radical intermediate from 13 is rapidly 
trapped by CYP2J2 iron, with the eventual formation of the iron-carbene complex, and is not 
released in the medium. 
 
CONCLUSION 
Starting from the structures of terfenadone and ebastine, 24 derivatives have been synthesized 
and evaluated as inhibitors of CYP2J2. Many of them exhibit a good affinity for this isoform 
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with IC50s at the micromolar level. A comparison of these IC50s has shown the importance of 
three structural features for a good recognition by CYP2J2: (i) the presence of a short 
hydrophobic alkyl chain at one end of the molecule, (ii) the presence of a keto group para to 
this alkyl chain on the terminal aryl group, and (iii) the presence of an hydrophobic 
diarylmethyl substituent at position 4 of the central piperidine ring. Four compounds appeared 
to be particularly interesting. Compound 14 is a good non-competitive (or mixed) inhibitor of 
CYP2J2 with an IC50 value of 400 ± 100 nM. It is not selective towards CYP2J2 as it also 
efficiently inhibits the other main vascular CYPs such as CYP2B6, 2C8, 2C9 and 3A4. 
However it could be an interesting tool to inhibit all these vascular CYPs. Compounds 4, 5 
and 13 are reasonably selective CYP2J2 inhibitors (Table 1). Compound 4 is a competitive 
inhibitor, alternative substrate of CYP2J2 of high-affinity (Ki = 160 ± 50 nM). Finally, 
compounds 5 and 13 are mechanism-based inhibitors of CYP2J2, characterized by high 
kinact/KI values (around 3000 L.mol-1.s-1) (Table 4). Inactivation of CYP2J2 by 13 is due to the 
formation of a very stable iron-carbene bond which occurs with a partition ratio of 18 ± 3. 
Compounds 4, 5 and 13 should be interesting tools to study the biological roles of CYP2J2. 
As far as vascular CYPs are concerned, Table 5 summarizes data obtained on 4 (this work, 
Table 1) and on ticlopidine [71, 72], montelukast [73], sulfaphenazole [74] and ketoconazole 
[74] as selective inhibitors of CYP2B6, 2C8, 2C9 and 3A4, respectively. These data show that 
each compound is a selective inhibitor of a given P450 – i.e. its IC50 for this CYP is at least 
20-fold lower than its IC50 towards the other P450s –, and exhibits a high affinity for its 
preferred P450 (IC50 values between 20 nM for montelukast and ketoconazole towards 
CYP2C8 and 3A4 respectively, to 600 nM for sulfaphenazole towards CYP2C9). This set of 
compounds should be very useful to determine the biological role of each P450 in the 
cardiovascular system. Finally, given the recent findings suggesting that CYP2J2 may 
  
27 
represent a potential target for therapy of human cancers [23], studies are currently underway 
to test the above described CYP2J2 inhibitors as potential therapeutic agents for cancer. 
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LEGENDS OF FIGURES 
 
Figure 1: Regioselectivity of the hydroxylation of ebastine and terfenadone by CYP2J2. 
 
Figure 2: General synthetic routes used for the preparation of terfenadone and ebastine 
derivatives. For the nature of R, see Table 1 and 2. Specific protection and deprotection of 
reactive chemical functions were used when necessary. They were mentioned in ref [28]. 
 
Figure 3: Dixon plots obtained from a kinetic study of CYP2J2-catalyzed hydroxylation 
of ebastine in the presence of different concentrations of compound 4. Results are means 
± SD calculated from three independent experiments, using microsomes of insect cells 
expressing CYP2J2, ebastine, 4, and a NADPH generating system, as described in Materials 
and Methods. Substrate concentrations used were 0.2 (■), 0.5 (∆), 2 (▲) and 5 µM (○). 
 
Figure 4: Lineweaver-Burk plots obtained from a kinetic study of CYP2J2-catalyzed 
hydroxylation of ebastine in the presence of different concentrations of compound 14. 
Results are means ± SD calculated from three independent experiments, using microsomes of 
insect cells expressing CYP2J2, ebastine, 14 and a NADPH generating system. Inhibitor 
concentrations used were 0 (□),0.5 (▲), 1 (○) and 2.5 µM (●). 
 
Figure 5: Kinetics of inactivation of CYP2J2 upon NADPH-dependent oxidation of 
compounds 5 (A) and 13 (B). Details for incubations and determination of remaining activity 
are described in Materials and Methods. CYP2J2 (30 nM) was incubated for the indicated 
times in the presence of a NADPH-generating system and 0 (■), 1 (□), 2 (▲), 5  (∆) and 20 
µM (○) compound 5 or 13. Values are means calculated from three independent experiments. 
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The inset shows the plot of t1/2 (time required for half-inactivation of CYP2J2) vs the 
reciprocal of the concentration of 5 or 13 for the experiments depicted (Kitz-Wilson plot).  
 
Figure 6: Possible mechanisms of the CYP2J2-catalyzed oxidation of 13 and of the 
inactivation of this cytochrome. 
 
Figure 7: Difference absorption spectra observed during CYP2J2-catalyzed oxidation of 
13 in the presence of NADPH. Conditions described in Materials and Methods; difference 
spectra obtained after 2,5, and 10 min after addition of 100 µM NADPH to the sample cuvette  
containing 0.1 µM CYP2J2 and 100 µM 13. 
 
Figure 8: Mass spectra of compound 13 and its metabolite formed after oxidation by 
CYP2J2. Mass spectra were obtained from HPLC-MS2 analysis of incubations of 50 µM 13 
with 10 nM CYP2J2 and a NADPH-generating system for 20 min, as described in Materials 
and Methods. The molecular fragments corresponding to the observed peaks are shown. (-
H2O: 250) indicates the fragment having lost H2O from dehydration of the tertiary alcohol 
function. 
 
Figure 9: Relationship between CYP2J2 inactivation and efficient catalysis of 13 
oxidation (catechol metabolite formation) (A) and determination of the partition ratio 
(B). Microsomes from insect cells expressing CYP2J2 were incubated with 2 µM 13 and a 
NADPH generating system (A). Values are means ± SD calculated from 3 independent 
experiments. Curve (B) was obtained from residual CYP2J2 activities and amounts of 
catechol metabolites measured from incubations of microsomes containing CYP2J2 in the 
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presence of a NADPH generating system and various concentrations of 13 (2-20 µM) for 
different time periods (0 to 30 min). Points are mean values from 3 experiments. 
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Figure 2 
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Figure 3 
 
